

Special Issue

Pancreatic Cancer Heterogeneity and Therapeutic Implications

Message from the Guest Editor

Dear colleagues, Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer with an abysmal prognosis and a 5-year overall survival of 9%. The only potential cure is surgery, but few patients present with resectable tumors at the time of diagnosis, which is often delayed by the vagueness of symptoms and the lack of specific clinical markers for early stages of PDAC. PDAC is also among the most chemoresistant cancers. Major obstacles to the effective treatment of patients with pancreatic cancer are its high heterogeneity translated in a diverse pattern of clinical outcomes and responses to therapies. There is a remarkably high histological heterogeneity between the PDAC tumors (intertumoral heterogeneity), but also within a single tumor (intratumoral heterogeneity). We welcome original and review papers that focus on the recent advances in the field of pancreatic cancer research, covering but not limited to 1) molecular insights of PDAC heterogeneity, 2) molecular mechanisms of innate and acquired resistance to therapy 3) characterization of tumor-stroma crosstalk and 4) potential novel targeted therapies. *Guest Editor*

Guest Editor

Dr. Tatjana Arsenijevic

1. Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, 1070 Brussels, Belgium
2. Department of Gastroenterology, Hepatology and Digestive Oncology, Hopital Universitaire de Bruxelles H.U.B. CUB Hopital Erasme, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162691

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).